ALEC - NASDAQ

Alector, Inc.

ALEC·NASDAQ

$1.77

-6.1%

HealthcareBiotechnology

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$197.07M

EPS-1.3900

P/E Ratio-1.28

Earnings Date08/06/2026

293.24M

Assets

-37%

3Y-63.0%

5Y-40.0%

10Y+442.0%

262.59M

Total Liabilities

-23%

3Y-54.0%

5Y+19.0%

10Y+232.0%

30.65M

Total Equity

-76%

3Y-86.0%

5Y-89.0%

10Y-223.0%

Alector, Inc. Funding & Solvency Profile

ALEC · NASDAQ

Current Assets

Cash & Cash Equivalents65.80M

Net Receivables0.00

Inventory0.00

Other Current Assets10.43M

Total Current Assets266 M

Non-Current Assets

Property, Plant & Equipment24.55M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets2.23M

Total Non-Current Assets27 M

Total Assets

293.24M

Financial Health Analysis

Current Ratio

3.83x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

8.57x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

197 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

91% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Alector, Inc. Balance Sheet

ALEC • NASDAQ

Alector, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	65.8M	33M	74.6M	154.3M	329.2M	50M	89.6M	65.5M	32.5M	50.8M
Short-Term Investments	190.2M	380.4M	474.3M	558.5M	406.1M	363.3M	263.4M	224.9M	0.0	0.0
Cash & Short-Term Investments	256M	413.4M	548.9M	712.9M	735.3M	413.3M	353.1M	290.4M	32.5M	50.8M
Net Receivables	0.0	0.0	0.0	2.6M	7.4M	0.0	0.0	0.0	200.2M	218K
Accounts Receivables	0.0	0.0	0.0	2.6M	7.4M	0.0	0.0	0.0	238K	218K
Prepaids	0.0	0.0	0.0	11M	7.1M	8.2M	4.4M	2.8M	285K	135K
Other Current Assets	10.4M	11.4M	16.9M	0.0	0.0	0.0	0.0	2.8M	0.0	0.0
Total Current Assets	266.5M	424.8M	565.8M	726.4M	749.7M	421.5M	357.4M	293.2M	233M	51.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	24.6M	37.1M	47.1M	53.3M	57.9M	62.7M	62.3M	10.9M	2.8M	2.5M
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	1.5M	1.5M	0.0	200K
Other Non-Current Assets	2.2M	6.4M	9M	7.9M	7M	4.1M	676K	2.8M	252K	184K
Total Non-Current Assets	26.8M	43.5M	56M	61.2M	64.9M	66.7M	64.5M	15.2M	3.1M	2.9M
Total Assets	293.2M	468.3M	621.8M	787.6M	814.7M	488.3M	421.9M	308.4M	236.1M	54.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.7M	2.2M	11.5M	4.2M	4.7M	3M	278K	126K	1.1M	1.2M
Accounts Payable	1.7M	2.2M	3.8M	4.2M	4.7M	3M	278K	126K	1.1M	1.2M
Other Payables	0.0	0.0	7.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	35.9M	20.3M	20.6M	24.5M	26.4M	5.7M	3.4M	1.7M	358K
Short Term Debt	9.4M	0.0	0.0	0.0	0.0	0.0	6.6M	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	8.8M	8.5M	8.1M	7.8M	7.5M	6.6M	0.0	0.0	0.0
Deferred Revenue	6.7M	23.7M	83M	48.2M	90.8M	23.9M	30.2M	34.9M	19M	0.0
Other Current Liabilities	51.7M	54.5M	54.7M	12.8M	11.7M	7.3M	-17.5M	9.6M	5.6M	0.0
Total Current Liabilities	69.5M	125.1M	177.9M	93.8M	139.6M	68.1M	31.8M	13M	27.4M	1.5M
NON-CURRENT LIABILITIES
Long Term Debt	26.8M	9.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	172.2M	210.8M	443.4M	334.4M	108.4M	153.4M	174.6M	183.2M	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	-194.9M	0.0	0.0	0.0
Other Non-Current Liabilities	166.3M	10.5M	68.4M	759K	158K	472K	493K	7.6M	77.5M	77.5M
Total Non-Current Liabilities	193.1M	216.4M	309.7M	479.4M	374.4M	152.6M	195.4M	392.7M	260.7M	77.5M
Capital Lease Obligations	0.0	33.1M	38.9M	43.3M	47.6M	51.3M	48M	0.0	0.0	0.0
Total Liabilities	262.6M	341.5M	487.7M	573.2M	513.9M	220.7M	227.2M	405.8M	288.1M	79M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	193.4M	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	421.9M	210.5M	77.5M	77.5M
Common Stock	11K	9K	8K	8K	8K	8K	7K	1K	1K	0.0
Additional Paid-In Capital	0.0	955.7M	844M	798.7M	748M	677M	414.4M	17.1M	10.2M	4.8M
Retained Earnings	-972.1M	-829.1M	-710.1M	-579.7M	-446.4M	-410M	-219.8M	-114.4M	-62.2M	-29.7M
Accumulated Other Comprehensive Income/Loss	166K	261K	184K	-4.6M	-943K	614K	142K	-42K	-980K	-300K
Other Total Stockholders' Equity	1B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	980K	300K
Total Stockholders' Equity	30.6M	126.8M	134.2M	214.4M	300.7M	267.5M	194.7M	-97.4M	-52M	-24.9M
Total Equity	30.6M	126.8M	134.2M	214.4M	300.7M	267.5M	194.7M	-97.4M	-52M	-24.9M
SUMMARY
Total Liabilities & Equity	293.2M	468.3M	621.8M	787.6M	814.7M	488.3M	421.9M	308.4M	236.1M	54.1M
Total Investments	190.2M	380.4M	474.3M	558.5M	406.1M	363.3M	263.4M	224.9M	0.0	200K
Total Debt	36.2M	42.5M	38.9M	43.3M	47.6M	51.3M	48M	0.0	0.0	0.0
Net Debt	-29.6M	9.5M	-35.6M	-111M	-281.6M	1.3M	-41.6M	-65.5M	-32.5M	-50.8M
Shares Outstanding	101,212,121	101,212,121	101,212,121	101,212,121	101,212,121	101,212,121	101,212,121	101,212,121	101,212,121	101,212,121

SEC Filings

ALEC - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	April 21, 2026	2026	View Filing
S-3 S-3 N/A	March 12, 2026	March 12, 2026		View Filing
10-K 10-K 2025 FY FY	February 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 12, 2025	December 10, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing

Showing 1 to 10 of 123 filings

Related Guides

Blog Categories

Continue your ALEC research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.